FDA Clears Neuromodulation Device for Acute Migraine Pain
The US Food and Drug Administration (FDA) has cleared the first noninvasive multichannel brain neuromodulation system to treat acute migraine pain. The Relivion system, from Neurolief, is an adjustable headset that delivers modulated pulses of electric current through adaptive output channels around the head to six branches of the occipital and trigeminal nerves. It is Cloud-enabled and linked to a mobile phone app. The device is designed to learn over time and to provide personalized therapy for individual patients, the company says.
@debjaan The FDA clearance of the Relivion non-invasive device is an important event for those suffering from migraines, as it is the only neuromodulation technology thus far that has demonstrated statistically significant efficacy in providing complete freedom of migraine symptoms within 2 hours after treatment, in a sham-controlled clinical trial